Our current development programs are focused on vaccines against COVID-19, Human Immunodeficiency Virus (HIV), Hemorrhagic Fever viruses such as Ebola (Zaire, Sudan), Marburg and Lassa, Malaria and Zika virus. We have also initiated programs to develop a multi-antigen vaccine to treat chronic Hepatitis B (HBV) infections, a vaccine to treat human papilloma virus (HPV)-induced cancers and a vaccine against tumor associated antigen MUC1 that is associated with metastatic progression of many cancer types including breast, ovarian, gastric, liver, pancreas, renal and  lymph nodes.